Regis Bataille
Overview
Explore the profile of Regis Bataille including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis
Capp J, Bataille R
Biology (Basel)
. 2023 Jul;
12(7).
PMID: 37508420
Multiple Myeloma (MM) and its preexisting stage, termed Monoclonal Gammopathy of Undetermined Significance (MGUS), have long been considered mainly as genomic diseases. However, the bone changes observed in both conditions...
2.
Capp J, Bataille R
Crit Rev Oncol Hematol
. 2022 Feb;
172:103640.
PMID: 35183697
The standard model of multiple myeloma (MM) oncogenesis from monoclonal gammopathy of undetermined significance (MGUS) relies on genetic instability in the normal counterparts of MM cells. However, the importance of...
3.
Capp J, Bataille R
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32759688
The standard model of multiple myeloma (MM) relies on genetic instability in the normal counterparts of MM cells. MM-induced lytic bone lesions are considered as end organ damages. However, bone...
4.
Pouzoullic M, Schott A, Sanchez-Rodriguez D, Bataille R, Annweiler C
Eur J Intern Med
. 2019 Aug;
68:51-54.
PMID: 31387843
The International Staging System (ISS) -calculated from serum albumin and beta-2 microglobulin (β2m)- is an established prognostic marker in multiple myeloma (MM), which has also been suggested to account for...
5.
Capp J, Bataille R
Front Oncol
. 2018 Sep;
8:355.
PMID: 30250824
The standard model of multiple myeloma (MM) oncogenesis is based on the genetic instability of MM cells and presents its evolution as the emergence of clones with more and more...
6.
Kervoelen C, Menoret E, Gomez-Bougie P, Bataille R, Godon C, Marionneau-Lambot S, et al.
Oncotarget
. 2015 Sep;
6(29):26922-34.
PMID: 26323097
Due to its cytotoxic effect in lymphoid cells, dexamethasone is widely used in the treatment of multiple myeloma (MM). However, only a subset of myeloma patients responds to high-dose dexamethasone....
7.
Bataille R, Annweiler C, Beauchet O
Clin Lymphoma Myeloma Leuk
. 2013 Sep;
13(6):635-7.
PMID: 24035714
Because of the wide variation in multiple myeloma (MM) survival, numerous studies have focused over the past 40 years on the biological and cytogenetic prognostic values in MM patients. Since...
8.
Surget S, Chiron D, Gomez-Bougie P, Descamps G, Menoret E, Bataille R, et al.
Cancer Res
. 2012 Jun;
72(17):4562-73.
PMID: 22738917
Myeloma cells are sensitive to TRAIL through the two death receptors DR4 and DR5. Because p53 directly modulates expression of death receptors, we investigated here whether p53 can modulate myeloma...
9.
Chiron D, Maiga S, Descamps G, Moreau P, Le Gouill S, Marionneau S, et al.
Blood Cells Mol Dis
. 2012 Feb;
48(4):247-53.
PMID: 22341562
The purpose of this study was to identify the pathways associated with the ability of CD138(+) human myeloma cells to form colonies in a serum-free semi-solid human collagen-based assay. Only...
10.
Bigot E, Bataille R, Patrice T
J Photochem Photobiol B
. 2011 Dec;
107:14-9.
PMID: 22169683
Photodynamic therapy (PDT) generates singlet oxygen ((1)O(2)) and Reactive Oxygen Species (ROS) that are counteracted by patient's defenses. As cancer treatments are among the most important PDT applications the aim...